A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

References

• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; http://dx.doi.org/10.1038/nri2744
   PubMed Web of Science ®Google Scholar
• Reichert JM. Which are the antibodies to watch in 2013? MAbs 2013; 5:1-4; PMID:23254906; http://dx.doi.org/10.4161/mabs.22976
   PubMed Web of Science ®Google Scholar
• Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23:1147-57; PMID:16151408; http://dx.doi.org/10.1038/nbt1137
   PubMed Web of Science ®Google Scholar
• Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008; 359:613-26; PMID:18687642; http://dx.doi.org/10.1056/NEJMra0708875
   PubMed Web of Science ®Google Scholar
• Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 2001; 11:130-5; PMID:11306274; http://dx.doi.org/10.1016/S0962-8924(00)01906-1
   PubMed Web of Science ®Google Scholar
• Jiang P, Lagenaur CF, Narayanan V. Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem 1999; 274:559-62; PMID:9872987; http://dx.doi.org/10.1074/jbc.274.2.559
   PubMed Web of Science ®Google Scholar
• Seiffert M, Brossart P, Cant C, Cella M, Colonna M, Brugger W, Kanz L, Ullrich A, Buhring HJ. Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. Blood 2001; 97:2741-9; PMID:11313266; http://dx.doi.org/10.1182/blood.V97.9.2741
   PubMed Web of Science ®Google Scholar
• Barclay AN, Brown MH. The SIRP family of receptors and immune regulation. Nat Rev Immunol 2006; 6:457-64; PMID:16691243; http://dx.doi.org/10.1038/nri1859
   PubMed Web of Science ®Google Scholar
• Tsai RK, Discher DE. Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 2008; 180:989-1003; PMID:18332220; http://dx.doi.org/10.1083/jcb.200708043
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, Jr., van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138:286-99; PMID:19632179; http://dx.doi.org/10.1016/j.cell.2009.05.045
   PubMed Web of Science ®Google Scholar
• Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010; 142:699-713; PMID:20813259; http://dx.doi.org/10.1016/j.cell.2010.07.044
   PubMed Web of Science ®Google Scholar
• Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012; 109:6662-7; PMID:22451913; http://dx.doi.org/10.1073/pnas.1121623109
   PubMed Web of Science ®Google Scholar
• Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 2011; 71:1374-84; PMID:21177380; http://dx.doi.org/10.1158/0008-5472.CAN-10-2238
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009; 138:271-85; PMID:19632178; http://dx.doi.org/10.1016/j.cell.2009.05.046
   PubMed Web of Science ®Google Scholar
• Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, Ozkan E, Fernhoff NB, van de Rijn M, Weissman IL, et al. Engineered SIRPalpha Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies. Science 2013. 341:88-91 ; PMID:23722425; http://dx.doi.org/10.1126/science.1238856
   PubMed Web of Science ®Google Scholar
• Theocharides AP, Jin L, Cheng PY, Prasolava TK, Malko AV, Ho JM, Poeppl AG, van Rooijen N, Minden MD, Danska JS, et al. Disruption of SIRPalpha signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med 2012; 209:1883-99; PMID:22945919; http://dx.doi.org/10.1084/jem.20120502
   PubMed Web of Science ®Google Scholar
• Chao MP, Weissman IL, Majeti R. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 2012; 24:225-32; PMID:22310103; http://dx.doi.org/10.1016/j.coi.2012.01.010
   PubMed Web of Science ®Google Scholar
• Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci 2011; 16:277-306; PMID:21196171; http://dx.doi.org/10.2741/3688
   PubMed Web of Science ®Google Scholar
• Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, Otten MA, Finetti P, Van Egmond M, Matozaki T, Kraal G, et al. CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A 2011; 108:18342-7; PMID:22042861; http://dx.doi.org/10.1073/pnas.1106550108
   PubMed Web of Science ®Google Scholar
• Muller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 2010; 24:89-98; PMID:20199124; http://dx.doi.org/10.2165/11530960-000000000-00000
   PubMed Web of Science ®Google Scholar
• May C, Sapra P, Gerber HP. Advances in bispecific biotherapeutics for the treatment of cancer. Biochem Pharmacol 2012; 84:1105-12; PMID:22858161; http://dx.doi.org/10.1016/j.bcp.2012.07.011
   PubMed Web of Science ®Google Scholar
• Fischer N, Leger O. Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 2007; 74:3-14; PMID:17496428; http://dx.doi.org/10.1159/000101046
   PubMed Web of Science ®Google Scholar
• Marvin JS, Zhu Z. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 2005; 26:649-58; PMID:15916729; http://dx.doi.org/10.1111/j.1745-7254.2005.00119.x
   PubMed Web of Science ®Google Scholar
• Holliger P, Prospero T, Winter G. Diabodies: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 1993; 90:6444-8; PMID:8341653; http://dx.doi.org/10.1073/pnas.90.14.6444
   PubMed Web of Science ®Google Scholar
• Deyev SM, Lebedenko EN. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. Bioessays 2008; 30:904-18; PMID:18693269; http://dx.doi.org/10.1002/bies.20805
   PubMed Web of Science ®Google Scholar
• Cheong HS, Chang JS, Park JM, Byun SM. Affinity enhancement of bispecific antibody against two different epitopes in the same antigen. Biochem Biophys Res Commun 1990; 173:795-800; PMID:1702631; http://dx.doi.org/10.1016/S0006-291X(05)80857-5
   PubMed Web of Science ®Google Scholar
• Neri D, Momo M, Prospero T, Winter G. High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J Mol Biol 1995; 246:367-73; PMID:7533215; http://dx.doi.org/10.1006/jmbi.1994.0091
   PubMed Web of Science ®Google Scholar
• Lu D, Kotanides H, Jimenez X, Zhou Q, Persaud K, Bohlen P, Witte L, Zhu Z. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. J Immunol Methods 1999; 230:159-71; PMID:10594363; http://dx.doi.org/10.1016/S0022-1759(99)00135-0
   PubMed Web of Science ®Google Scholar
• Dorvillius M, Garambois V, Pourquier D, Gutowski M, Rouanet P, Mani JC, Pugniere M, Hynes NE, Pelegrin A. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen. Tumour Biol 2002; 23:337-47; PMID:12677091; http://dx.doi.org/10.1159/000069793
   PubMed Web of Science ®Google Scholar
• Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99:1415-25; PMID:18841159; http://dx.doi.org/10.1038/sj.bjc.6604700
   PubMed Web of Science ®Google Scholar
• Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010; 47:107-14; PMID:20350657; http://dx.doi.org/10.1053/j.seminhematol.2010.01.001
   PubMed Web of Science ®Google Scholar
• Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
   PubMed Web of Science ®Google Scholar
• Wu C, Ying H, Bose S, Miller R, Medina L, Santora L, Ghayur T. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 2009; 1:339-47; PMID:20068402; http://dx.doi.org/10.4161/mabs.1.4.8755
   PubMed Web of Science ®Google Scholar
• Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, Vandlen RL. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005; 44:15150-8; PMID:16285718; http://dx.doi.org/10.1021/bi0511078
   PubMed Web of Science ®Google Scholar
• Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood 2006; 108:1975-8; PMID:16705086; http://dx.doi.org/10.1182/blood-2006-04-014639
   PubMed Web of Science ®Google Scholar
• Khandelwal S, van Rooijen N, Saxena RK. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion 2007; 47:1725-32; PMID:17725740; http://dx.doi.org/10.1111/j.1537-2995.2007.01348.x
   PubMed Web of Science ®Google Scholar
• Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174:6477-89; PMID:15879151; http://dx.doi.org/10.4049/jimmunol.174.10.6477
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol 2010; 31:212-9; PMID:20452821; http://dx.doi.org/10.1016/j.it.2010.04.001
   PubMed Web of Science ®Google Scholar
• Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. Cell Stem Cell 2012; 10:120-36; PMID:22305562; http://dx.doi.org/10.1016/j.stem.2012.01.006
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2013: Mid-year update. MAbs 2013; 5:513-7; PMID:23727858; http://dx.doi.org/10.4161/mabs.24990
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-45; PMID:7506951
   PubMed Web of Science ®Google Scholar
• Gresham HD, Goodwin JL, Allen PM, Anderson DC, Brown EJ. A novel member of the integrin receptor family mediates Arg-Gly-Asp-stimulated neutrophil phagocytosis. J Cell Biol 1989; 108:1935-43; PMID:2785522; http://dx.doi.org/10.1083/jcb.108.5.1935
   PubMed Web of Science ®Google Scholar
• Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992; 52:6761-7; PMID:1458463
   PubMed Web of Science ®Google Scholar
• Huang X, Wilber AC, Bao L, Tuong D, Tolar J, Orchard PJ, Levine BL, June CH, McIvor RS, Blazar BR, et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood 2006; 107:483-91; PMID:16189271; http://dx.doi.org/10.1182/blood-2005-05-2133
   PubMed Web of Science ®Google Scholar